| pubmed-article:12920037 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C1332225 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C1879501 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C1413947 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C1442989 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C0055598 | lld:lifeskim |
| pubmed-article:12920037 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:12920037 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:12920037 | pubmed:dateCreated | 2003-12-5 | lld:pubmed |
| pubmed-article:12920037 | pubmed:abstractText | We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in previously untreated patients with poor-risk aggressive lymphoma. Patients aged 61 to 69 years who had aggressive non-Hodgkin lymphoma with at least one prognostic factor of the age-adjusted international prognostic index (IPI) were included. ACVBP consisted of an induction phase of intensified chemotherapy and central nervous system (CNS) prophylaxis followed by a sequential consolidation phase. Of the 708 patients registered for the study, 635 were eligible. The rate of complete response was 58% in the ACVBP group and 56% in the CHOP group (P =.5). Treatment-related death occurred in 13% of the ACVBP group and 7% of the CHOP group (P =.014). At 5 years, the event-free survival was 39% in the ACVBP group and 29% in the CHOP group (P =.005). The overall survival was significantly longer for patients treated with ACVBP, at 5 years it was 46% compared with 38% for patients treated with CHOP (P =.036). CNS progressions or relapses were more frequent in the CHOP group (P =.004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival. | lld:pubmed |
| pubmed-article:12920037 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12920037 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920037 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12920037 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:12920037 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:Groupe... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:FilletGeorges... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:AttalMichelM | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:CoiffierBertr... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:LepageEricE | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:HerbrechtRaou... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:ReyesFelixF | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:GisselbrechtC... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:BoslyAndreA | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:TillyHerveH | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:GuettierCathe... | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:BlancMichelM | lld:pubmed |
| pubmed-article:12920037 | pubmed:author | pubmed-author:MolinaThierry... | lld:pubmed |
| pubmed-article:12920037 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12920037 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:12920037 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:12920037 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12920037 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12920037 | pubmed:pagination | 4284-9 | lld:pubmed |
| pubmed-article:12920037 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:meshHeading | pubmed-meshheading:12920037... | lld:pubmed |
| pubmed-article:12920037 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12920037 | pubmed:articleTitle | Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. | lld:pubmed |
| pubmed-article:12920037 | pubmed:affiliation | Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France. herve.tilly@rouen.fnclcc.fr | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:12920037 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12920037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12920037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12920037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12920037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12920037 | lld:pubmed |
